~~<i id='E3602BD5E4'><strike id='E3602BD5E4'><tt id='E3602BD5E4'><pre id='E3602BD5E4'></pre></tt></strike></i>~~

Home» knowledge» knowledge

knowledge

author：knowledge 2025-10-06 06:26:34 Page View：87

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Test for long Covid? Researchers find new clue in blood samples
Next article： As demand for Covid shots wanes, Moderna seeks its next success

explore

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

eGenesis tests gene

Agene-editedYucatanminipigcreatedbyeGenesis.CourtesyLizLinder/eGenesisForthreedaysinDecember,anICUro

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

My yearlong odyssey to get my son’s ADHD medication covered

AdobeLastJanuary,Iwenttofillmyson’sADHDprescriptionandwashandedabagwithanunfamiliardrugnameonit.Nomi